.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, clients with metastatic stomach lumps that received biomarker-matched therapies based on circulating lump DNA profiling revealed a greater professional perk than those receiving unrivaled treatment.